<DOC>
	<DOCNO>NCT02308098</DOCNO>
	<brief_summary>The purpose study confirm equivalent bronchodilator efficacy test product compare reference product .</brief_summary>
	<brief_title>To Confirm Equivalent Bronchodilator Efficacy Test Product Compared Reference Product</brief_title>
	<detailed_description />
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>Main inclusion criterion : Written inform consent Asthma diagnosis least 6 month Prebronchodilator FEV1 4590 % predict value Demonstration reversible airway obstruction Stable asthma regular treatment least 4 week study Nonsmoker least 6 month study Main exclusion criterion Respiratory infection within 4 week study Smoking history 10 packyears Other severe chronic respiratory disease asthma Concurrent illness would interfere interpretation study result constitute health risk patient he/she take part study Corrected QT interval &gt; 450 m male &gt; 470 m female Abnormal serum potassium value clinically significant laboratory find Systolic blood pressure 180 mmHg and/or diastolic blood pressure 100 mmHg Treatment longacting β2agonist , xanthinederivative , βblocker corticosteroid ( inhale ) within 4 week study Use drug prolong QTinterval Women pregnant , breastfeed without reliable contraception Participation another clinical drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>